Slow Sunday mornings are perfect for perusing magazine racks in my local bookstore. In full disclosure I am usually interested in innovative design and travel but I couldn't avoid the headline of the latest issue of Fortune. If you follow the blog with any regularity, I attempt to humanize the history of Alzheimer's Disease, follow the economics, and clarify claims and forward thinking research findings often bolstered to a frenzied pitch. Biogen specifically was featured in a recent blog but this May cover story cited "229 Alzheimer's Drugs Failed from 2002 to 2012" and "Alzheimer's Cost the US $214 billion in 2014. I was anticipating context and good science but instead I was reminded of the source of the story, Fortune is self-proclaimed as "The world’s most respected business publication delivers expert advice to help you optimize your career along with in-depth analysis of technology, business, and economic trends and breakthroughs."
A data analyst focuses the lens on the evolution of Alzheimer's Disease as a diagnosis into a billion dollar healthcare juggernaut
Sign up for newsletter:
ADTB remains a labor of love. It honors my dad and his journey with Alzheimer's disease.
I spend quite a bit of time traveling and researching and hope to publish an expanded discussion of many of these insights.
If you are able to and indeed benefit from my efforts I would appreciate your donation to keep the site ad-free and relevant.
How about enough for a coffee? Any amount is appreciated. Thank you!
Follow our blog about the intersection of health policy, economics, and clinical medicine.